Cerus Reports Q2 Revenue Growth, Raises Full-Year Guidance
Cerus Corporation (NASDAQ:CERS) reported second-quarter product revenue of $57.4 million, a 10% increase year over year and contributing to first-half revenue growth of 16%. The company raised its full-year 2026 product revenue guidance to between $229 million and $231 million from the previous range of $227 million–$231 million. IFC (INTERCEPT Fibrinogen Complex) demand accelerated, with U.S. sales up about 20% in Q2; Cerus expects nearly all IFC sales to transition to higher-margin kits by 2027. Adjusted EBITDA remained positive at $3 million for the quarter and is expected to improve further due to refinancing efforts that will reduce annual interest expenses by up to $3.5 million. The company also advanced its pipeline, submitting materials for INT200 platelet-device approval with the FDA and remains on track for Phase III red-blood-cell trial results in Q4 2026. If approved, INT200 could be available as early as H1 2027. Cerus is expanding internationally, with EMEA revenue up 10% year over year (excluding currency effects), and has a strong presence in North America where INTERCEPT for platelets is the standard of care. The company's partnership with Blood Centers of America also contributed to growth.
Tickers: $CERS